XOMA Royalty Corp.
NASDAQ:XOMABiotechnology
+$0.19 today
- Market cap
- $503.77M
- Beta
- 0.87
- P/E (TTM)
- 15.8
- EPS (TTM)
- $2.65
Volume 4.22M
Average 0.21M
XOMA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
XOMA Royalty Corp.NASDAQ: XOMA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $11.86M rose 45.6% year over year, ahead of the -35.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 13.9% from the prior quarter. Over 3 fiscal years it compounded at +15.9% a year.
Context
- Selling, general & admin amounted to 69.2% of revenue in FY2025, down 51.8 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $145.75M (+303.8%) for the fiscal year ending Dec 2026, a step up from the +4.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $11.86M+13.9% QoQ
- Last fiscal yearDec 2025
- $36.09M+4.7% YoY
- LTMMar 2026
- $39.8M-35.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 36.09M USD
- Year-over-year change
- +4.7%
- 4-year CAGR
- +15.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.09M | +4.7% |
| FY2024 | 2024-12-31 | 34.48M | +26.8% |
| FY2023 | 2023-12-31 | 27.18M | +17.2% |
| FY2022 | 2022-12-31 | 23.19M | +13.3% |
| FY2021 | 2021-12-31 | 20.46M | — |
Selling, General & Admin vs competitors
How XOMA compares with its peers on the latest reported figures
- XOMA's LTM Mar 2026 selling, general & admin of $39.8M is the 5th highest of the 10 companies compared; the peer median is $34.74M.
- Its year-over-year change of -35.2% is the lowest of 10, against a peer median of +11.6%.
- Selling, general & admin amounts to 109.9% of revenue for XOMA, versus a peer median of 1224.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $142.24M | +17.3% | +60.5% | 153.6% | |
| LTM Mar 2026 | $75.11M | -30.1% | +13.7% | — | |
| LTM Mar 2026 | $42.51M | -16.5% | +1.9% | 2295.5% | |
| LTM Mar 2026 | $40.91M | +18.8% | +10.3% | — | |
| LTM Mar 2026 | $39.8M | -35.2% | +15.9% | 109.9% | |
| LTM Mar 2026 | $34.74M | +87.8% | +52.2% | — | |
| LTM Mar 2026 | $23.71M | +3.3% | +7.6% | — | |
| LTM Mar 2026 | $20.62M | +11.6% | +2.3% | — | |
| LTM Mar 2026 | $9.79M | +21.7% | +16.7% | — | |
| LTM Mar 2026 | $6.23M | +9.7% | -4.3% | — | |
| Peer median (excluding XOMA) | $34.74M | +11.6% | +10.3% | 1224.6% | |
Competitors are the stored peer set for XOMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 38.16M | 6.03M | 4.76M | 28.49M | 52.15M |
| Cost of Revenue | 171K | 274K | 143K | 206K | 2.96M |
| Gross Profit | 37.99M | 5.75M | 4.62M | 28.28M | 49.18M |
| Gross Margin | 99.6% | 95.5% | 97.0% | 99.3% | 94.3% |
| Research & Development | 171K | 153K | 143K | 2.88M | 1.71M |
| Selling, General & Admin | 20.46M | 23.19M | 27.18M | 34.48M | 36.09M |
| Operating Expenses | 20.46M | 23.17M | 46.46M | 68.26M | 37.79M |
| Depreciation & Amortization | 167K | 274K | 900K | 216K | 2.97M |
| EBITDA | 16.52M | (16.85M) | (22.56M) | (5.42M) | 47.82M |
| EBITDA Margin | 43.3% | -279.5% | -474.2% | -19.0% | 91.7% |
| Operating Income | 17.53M | (17.41M) | (41.85M) | (39.98M) | 11.38M |
| Operating Margin | 45.9% | -288.9% | -879.5% | -140.3% | 21.8% |
| Interest Income | 0 | 694K | 0 | 0 | 0 |
| Interest Expense | 461K | 0 | 569K | 13.84M | 13.03M |
| Other Income / Expenses | (1.64M) | 295K | 1.02M | 20.5M | 20.43M |
| Income Before Tax | 15.89M | (17.12M) | (40.83M) | (19.48M) | 31.82M |
| Pre-Tax Margin | 41.6% | -284.0% | -858.2% | -68.4% | 61.0% |
| Income Tax Expense | 91K | (15K) | 0 | (5.66M) | 103K |
| Net Income | 15.8M | (17.1M) | (40.83M) | (13.82M) | 31.71M |
| Net Margin | 41.4% | -283.8% | -858.2% | -48.5% | 60.8% |
| EPS (Basic) | 0.69 | (1.98) | (4.04) | (1.65) | 1.53 |
| EPS (Diluted) | 0.65 | (1.98) | (4.04) | (1.65) | 1.46 |
| Weighted Avg Shares | 11.29M | 11.41M | 11.47M | 11.7M | 17.98M |
| Weighted Avg Shares (Diluted) | 12.19M | 11.41M | 11.47M | 11.7M | 17.98M |
XOMA Royalty Corp.
NASDAQ:XOMA
Intrinsic Alpha fair value
Locked
Current Price
$40.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.